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Abstract
Background: A standardized imaging proposal evaluating implanted left atrial appendage (LAA) occlusion devices
by cardiac computed tomography angiography (cCTA) has never been investigated.
Methods: cCTA datasets were acquired on a 3rd generation dual-source CT system and reconstructed with a slice
thickness of 0.5 mm. An interdisciplinary evaluation was performed by two interventional cardiologists and one
radiologist on a 3D multi-planar workstation. A standardized multi-planar reconstruction algorithm was developed
in order to assess relevant clinical aspects of implanted LAA occlusion devices being outlined within a pictorial
essay.
Results: The following clinical aspects of implanted LAA occlusion devices were evaluated within the most
appropriate cCTA multi-planar reconstruction: (1) topography to neighboring structures, (2) peri-device leaks,
(3) coverage of LAA lobes, (4) indirect signs of neo-endothelialization. These are illustrated within concise CT
imaging examples emphasizing the potential value of the proposed cCTA imaging algorithm: Starting from
anatomical cCTA planes and stepwise angulation planes perpendicular to the base of the LAA devices
generates an optimal LAA Occluder View for post-implantation Evaluation (LOVE). Aligned true axial, sagittal
and coronal LOVE planes offer a standardized and detailed evaluation of LAA occlusion devices after
percutaneous implantation.
Conclusions: This pictorial essay presents a standardized imaging proposal by cCTA using multi-planar
reconstructions that enables systematical follow-up and comparison of patients after LAA occlusion device
implantation.
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Background
The left atrial appendage (LAA) represents the main ori-
gin of thrombus formation in atrial fibrillation, where the
principles of Virchow’s triad, such as dysfunction and
structural changes of the endothelium as well as abnormal
blood stasis and homoeostasis are present [1–3]. The im-
plantation of LAA occlusion devices in patients with atrial
fibrillation was shown to prevent cardio-embolic stroke as
safe and effective as the treatment with the oral anti-
coagulant warfarin in patients eligible for oral anticoagula-
tion [2–10]. However, the anatomic morphology of the
LAA is highly variable and influences independently
the incidence of cardio-embolic stroke [11, 12]. The
common classification distinguishes four different LAA
morphologies, which can be evaluated at best by com-
puted tomography imaging [12–14]: 1. chicken wing, 2.
cactus, 3. windsock, 4. cauliflower. All these morpholo-
gies differ extremely by the number of different LAA
lobes, folds, tortuosities, diameters and global sizes and
complicate individually the percutaneous implantation
of LAA occlusion devices. Interestingly, the chicken
wing was shown to be associated with lowest rates of
cardio-embolic stroke compared to all other LAA
morphologies [12].
The WATCHMAN (WM) (Boston Scientific, Natick,
MA, USA) and Amplatzer Cardiac Plug (ACP) (St. Jude
Medical, St Paul, MN, USA) represent the most commonly
implanted LAA occlusion devices with valuable scientific
evidence being available at present [2, 7, 15, 16]. Until now,
trans-esophageal echocardiography (TEE) is most often ap-
plied to guide LAA occlusion device implantation, posi-
tioning and sealing both during percutaneous intervention
and follow-up after device implantation [17–19]. It was
shown that healing response after implantation of these
devices differs and might result in harmful impact on
neighboring structures [20]. However, a standardized im-
aging proposal for post-implantation evaluation of LAA
occlusion devices by cardiac computed tomography
(cCTA) has never been developed.
Therefore, this pictorial essay aims to develop this
standardized imaging proposal by cCTA in order to
analyze relevant clinical aspects of LAA occlusion de-
vices after percutaneous implantation. This cCTA im-
aging proposal outlines relevant clinical aspects such as
device positioning in relation to the varying morph-
ology and topography of the LAA as well as functional
device aspects such as peri-device leaks, lobe coverage
and neo-endothelialization of the device and demonstrates
illustrations of these conditions.
Methods
Ethics, consent and permissions
All participants of the presented patient-related data
within this pictorial assays gave written consent to this
analysis. The analyses were carried out according to the
principles of the declaration of Helsinki and was ap-
proved by the medical ethics commission II of the Fac-
ulty of Medicine Mannheim, University of Heidelberg,
Germany.
Cardiac CTA (cCTA) protocol and image reconstruction
advice for post-implantation evaluation of LAA occlusion
devices
Based on our experience, cCTA protocols for the evalu-
ation of LAA occlusion devices do not require signifi-
cant protocol adjustments, when compared to standard
cCTA protocols being performed for the evaluation of
coronary artery stenosis [21–24]. Optimal hydration of
the patient is recommended in order to achieve best
measurements. Similar to a standard cCTA acquisition
contrast injection should be performed with a flow rate
of at least 5 cc/s followed by a saline chaser in order to
have a compact contrast bolus that is washed out mainly
in the right atrium and right ventricle during the image
acquisition. Depending on the patients’ heart rate all
available cCTA acquisition protocols in principle qualify
for the evaluation of LAA occlusion devices including
traditional retrospective ECG gating, prospective ECG
triggering as well as high pitch or single heart beat
acquisitions [25]. However, since there is no dedicated
recommendation and clinical requirement for post-im-
plantation evaluation of LAA occlusion devices in all
patients, the acquisition technique that provides the
lowest radiation dose depending on the available CT
system should be applied. Hereby, a slightly lower
image quality of the coronary arteries can be accepted
since the LAA is not prone particularly to motion arti-
facts such as for instance the right coronary artery.
Prospective ECG triggered cCTA acquisitions or single
heart beat acquisitions can be used in patients with
high heart rates or arrhythmias. However, different to
a standard cCTA in patients with a low and regular
heart rate an end-systolic image acquisition was ap-
plied for the evaluation of LAA occlusion devices in
all patients independently from the heart rate in order
to acquire the image data during the maximum disten-
sion of the left atrium and LAA.
Reconstruction of cCTA raw data was performed with
a slice thickness between 0.5 and 0.6 mm using a sharp
convolution kernel that is also used for the reconstruc-
tion of cCTA images in patients with coronary artery
stent grafts or heavily calcified plaques. If available itera-
tive reconstruction techniques should be used to lower
image noise and blooming artifacts originating from
metal components of the devices [26–28]. Table 1 sum-
marizes the proposed cCTA protocol of patients after
LAA occlusion device implantation.
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Generating a standardized proposal by multi-planar imaging
0.6 mm thick images reconstructed with a medium
convolution kernel are uploaded on a simple 3D multi-
planar rendering workstation with the 3 planes locked at
a 90° angle (Figs. 1 and 2, panels I) (Additional files 1
and 2). The axial slices should be moved to the level of
the left atrium, in which the LAA occlusion device is
visible (Figs. 1 and 2, panels II). These initial steps are
independent of different type of implanted LAA occlu-
sion devices (either WM or ACP).
Amplatzer cardiac plug (ACP) device
Specifically for the ACP device, move the coronal axis
within the transverse window perpendicular to the disc
of the ACP device (Fig. 1, panel III). Afterwards, align
the axes on the two other viewers also perpendicular to
the disc of the ACP device (Fig. 1, panels IV and V).
Lastly, the center of the axes should be placed to the
center of the screw-hub.
WATCHMAN (WM) device
Since the WM device is not equipped with a disc, the
alignment might become more challenging. Here, using
maximum intensity projection (MIP) images with a slab
thickness of approximately 10 mm allows visualization of
the whole nitinol frame of the WM device. Afterwards,
move the coronal axis within the transverse window per-
pendicular to the coves of the parachute of the WM de-
vice (Fig. 1, panel III). Afterwards, align the axes on the
two other viewers also perpendicular to the coves of the
parachute of the ACP device (Fig. 1, panels IV and V).
Lastly, the center of the axes should be placed to the cen-
ter of the screw-hub.
Starting from anatomical cCTA planes while applying
all of the described imaging steps above will generate the
optimal LAA Occluder View for post-implantation Evalu-
ation (LOVE) (Figs. 1 and 2, Additional files 1, 2, 3 and 4).
This standardized imaging reconstruction view can be ap-
plied for the two most commonly implanted LAA occlu-
sion devices (i.e. ACP and WM). The LOVE view allows
optimal evaluation of the most relevant clinical aspects of
the post-implantation follow-up of patients with LAA oc-
clusion devices: (1) peri-device leaks, (2) coverage of LAA
lobes, (3) indirect signs of neo-endothelialization.
Results
Clinical scenarios reflecting relevant clinical aspects after
implantation of LAA occlusion devices
Imaging reports about percutaneously implanted LAA
occlusion devices should focus on the following import-
ant clinical aspects:
Morphologic and topographic aspects of LAA occlusion
device positioning
 Global positioning of the device including rotation
around the entry axis to the LAA. This can be best
measured on LOVE axial and LOVE sagittal views.
Table 1 Protocol example for imaging of LAA occlusion devices using a 3rd generation dual source CT system
Heart rate <70 bpm Heart rate 71–85 bpm Heart rate >85 Arrhythmia
cCTA technique High pitch single heart beat
acquisition
Prospective ECG gating (step-
and-shot)
Retrospective ECG gating Retrospective ECG gating
Tube voltage BMI <28: 70 kVp BMI <28: 70 kVp BMI <28: 70 kVp BMI <28: 70 kVp
BMI 28.1–30: 80 kVp BMI 28.1–30: 80 kVp BMI 28.1–30: 80 kVp BMI 28.1–30: 80 kVp
BMI 30.1–33: 90 kVp BMI 30.1–33: 90 kVp BMI 30.1–33: 90 kVp BMI 30.1–33: 90 kVp
BMI >33: 100–120 kVp BMI >33: 100–120 kVp BMI >33: 100–120 kVp BMI >33: 100–120 kVp
Tube current-time
product
Automated tube current
modulation (Care Dose 4D,
Siemens)
Automated tube current
modulation (Care Dose 4D,
Siemens)
Automated tube current
modulation (Care Dose 4D,
Siemens)
Automated tube current
modulation (Care Dose 4D,
Siemens)
Slice thickness 0.6 mm 0.6 mm 0.6 mm 0.6 mm
Reconstruction
increment
0.4 0.4 0.4 0.4
Reconstruction
kernel
Bv40 (vascular kernel)
(Siemens)
Bv40 (vascular kernel)
(Siemens)
Bv40 (vascular kernel)
(Siemens)
Bv40 (vascular kernel)
(Siemens)
Reconstruction
phase
70 % RR 40–70 % RR 20–70 % RR 10–90 % RR
Reconstruction
technique
Iterative reconstruction level III
(ADMIRE, Siemens)
Iterative reconstruction level III
(ADMIRE, Siemens)
Iterative reconstruction level III
(ADMIRE, Siemens)
Iterative reconstruction level III
(ADMIRE, Siemens)
Contrast medium 80 cc iomeprol 400 (Bracco)a 80 cc iomeprol 400 (Bracco)a 80 cc iomeprol 400 (Bracco)a 80 cc iomeprol 400 (Bracco)a
Note: bpm: beats per minute; kVp: kilovoltage peak; ECG: electrocardiograma contrast material is not reduced as it is possible for a standard coronary CT
angiography in order to reduce blood stasis artifacts within the left atrial appendage; the scan start is determined using bolus tracking within the descending
aorta using a threshold of 120 HU and an additional delay of 7 s in order to have a slightly delayed scan start when compared to standard
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 LOVE axial views allow optimal evaluation of global
compression of both devices:
WM device: compression of 10–20 % referred to the
original device size is recommended.
ACP device: concave disc; device lobe positioned 2/3
distal to the LCX inside and engaged within the LAA;
ACP device axis in line with the LAA neck axis.
 LOVE axial views allow optimal evaluation of
impairment to neighboring structures by the LAA
occlusion device: including positioning in relation to
the mitral valve annulus, pulmonary artery, left
pulmonary veins as well as LCX that is best visible
in LOVE axial views (Fig. 3).
Functional aspects of LAA occlusion devices
 Peri-device leaks:
These can be seen best on LOVE sagittal views. The
presence of a peri-device leak should be measured in
all reports (Figs. 4, 5 and 6). Higher resolution
measurements of peri-device leak diameters can be
performed by cCTA compared to TEE. Accordingly,
further studies are needed to evaluate the additional
value of cCTA measurements in this context and
whether definitions of the PROTECT AF study can
accordingly be transferred (i.e. minor (<1 mm
width), moderate (1 to 3 mm width) or major
Fig. 1 Illustration of a stepwise standard multimodal imaging to generating optimal LAA Occluder View for post-implantation Evaluation (LOVE)
planes from anatomical cCTA planes. Figure shows 5 standardized steps (panels I-V) for the ACP® device
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(3 mm width)). A sole peri-device leak should be
reported in case the sealing part of the device (either
proximal disk or cap) is parallel to the plane of the
LAA ostium. Remaining contrast filling will then be
visible around the device on the LOVE views
(Fig. 6).
 Coverage of all lobes:
The LAA often consists of different lobes not
corresponding necessarily to the fixed shape of the
LAA occlusion device. Therefore, complete coverage
of all LAA lobes is not always achievable.
Assessment of lobe coverage should consider the
angle between the sealing part of the device
(either proximal disk or cap) and the plane of the
LAA ostium. This angle corresponds to the
incompletely covered LAA lobe. Accordingly,
Fig. 7 illustrates a small residual LAA lobe due to
over-angulation of the device. Rotation around the
entry axis to the LAA should be measured on
LOVE axial and LOVE sagittal views. Lobe
coverage should be assessed on all LOVE
reformations (Figs. 4, 5, 7 and 8).
Fig. 2 Illustration of a stepwise standard multimodal imaging to generating optimal LAA Occluder View for post-implantation Evaluation (LOVE)
planes from anatomical cCTA planes. Figure shows 5 standardized steps (panels I-V) for the WATCHMAN® device
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 Complete neo-endothelialization:
Absence of contrast enhancement within the LAA
without any peri-device leak suggests complete
neo-endothelialization. Accordingly, contrast
enhancement in the LAA of less than 50 Hounsfield
units compared to the left atrium suggests incomplete
neo-endothelialization. Equal contrast enhancement
in both LAA and left atrium suggests no or very early
stages of neo-endothelialization (Figs. 4, 5, 7 and 8).
Discussion
This pictorial essay presents a standardized imaging pro-
posal by cCTA using multi-planar reconstructions that en-
ables systematical follow-up and comparison of patients
after LAA occlusion device implantation. As described
above and being accompanied by a case series of striking
illustrations this imaging proposal intends to cover the
most relevant clinical challenges of implanted LAA occlu-
sion devices including morphologic, topographic as well
as functional device-related aspects. The presented im-
aging proposal generates novel hypotheses, which have to
be proven by ongoing prospective, randomized imaging
studies.
Based on the so far available literature on safety and
patient outcome, it is likely that the number of patients
undergoing percutaneous LAA occlusion device im-
plantation will raise significantly within the near future
similar to the growing number of patients undergoing
transcatheter aortic valve replacement (TAVR). However,
in order to identify patients with poor outcome and/or
post-procedural complications, such as a residual LAA
larger than a specific device size that still leads to
thrombus formation, accurate, reproducible and reader-
independent imaging is crucial. This is of particular
importance in order to generate more evidence about
optimal placement of LAA occlusion devices.
For instance, the presence of relevant peri-device leaks
or incomplete coverage of residual LAA lobes might be
Fig. 3 LOVE coronal (panel a) and sagittal (panel b) reformations demonstrating the anatomic relationship to relevant neighboring structures that
should be reported. Panel a shows the close anatomic relationship to the left upper pulmonary vein (LUPV) and the left circumflex coronary
artery (LCX) that is adjacent directly to the LAA occlusion device (* in panels a and b). The pulmonary artery (PA) is the third relatively close
neighboring structure that should be inspected carefully on LOVE axial reformations
Fig. 4 The figure summarizes schematically the four main follow-up scenarios on cardiac CTA after LAA occlusion device implantation. Panel a
demonstrates optimal positioning of the LAA occlusion device without any residual lobe, any peri-device leak and without any residual contrast
filling (blue dots in LAA) indicating complete neo-endothelialization. Panel b demonstrates a peri-device leak with contrast filling of the LAA.
Panel c shows sub-optimal positioning of the LAA occlusion device with in-complete lobe coverage leaving a residual left atrial appendage.
Panel d shows optimal positioning of the LAA occlusion device with in-complete neo-endothelialization that is suggested indirectly by the
contrast enhancement of the LAA (blue dots in LAA). Please note that all three scenarios can occur in combination. In case of an existing peri-device
leak with contrast filling of the LAA assessment of endothelialization is not feasible with cardiac CT
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Fig. 5 LOVE - axial (panel a), − sagittal (panel b), - coronal (panel c), and 3D (panel d) reformations of a 72 year-old male patient who underwent
cardiac CTA 9 months after implantation of a ACP® LAA occlusion device. Panels a, b, and c show optimal positioning of the device with no
peri-device leak, complete lobe coverage as well as complete neo-endothelialization of the device suggested by the absence of contrast
enhancement < 50 Hounsfield units in the LAA (* in B and C). Volume rendered reconstructions
Fig. 6 LOVE - axial (panel a), − sagittal (panel b), and - coronal (panel c) reformations of a 80-year-old male patient who underwent cardiac CTA
8 months after implantation of a WATCHMAN® LAA occlusion device. Panels a and c show a small peri-device leak <3 mm at the cranial LAA
entry causing complete contrast filling of the LAA (white arrow). Panel b demonstrates the correct positioning of the device with complete lobe
coverage, as indicated by the correctly positioned sealing part (proximal cap of the WM device) parallel to the plane of the LAA ostium (red line).
Due to the presence of the peri-device leak the assessment of endothelialization is not feasible with cardiac CTA
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associated with individually impaired neurologic out-
come of the patients. These mal-appositions of LAA
occlusion devices have been attributed to clinical overt
neurologic disability and silent cerebral ischemia being
caused by cerebral micro-embolism and visualized by
cerebral magnetic resonance imaging (cMRI) [17]. Im-
portantly, cCTA might also allow the evaluation of
complete neo-endothelialization of the LAA occlusion
device. From the treating physician’s perspective complete
neo-endothelialization without any peri-device leak might
facilitate future clinical decision-making to stop concomi-
tant anticoagulation or dual antiplatelet therapy (DAPT).
Little is known regarding incidences of device related
complications after successful percutaneous implant-
ation of LAA occlusion devices, such as device com-
pression, peri-device leaks, lobe coverage and progress
of neo-endothelialization related to study-specific anti-
thrombotic treatments. The latter were evaluated for
DAPT (i.e. aspirin and clopidogrel) lasting 6 months, as
within the present study, or for warfarin for 45 days,
followed by clopidogrel for 4.5 months and lifelong as-
pirin [2, 7, 10, 16]. There is a lack of data comparing
the quality of TEE versus CT follow-up imaging after
device implantation and the optimal time period still
needs to be investigated. Device compression and shape
in relation to surrounding vessels is of importance for
optimal device and hemodynamic stability over time in
order to prevent relevant dislodgment or obstruction of
neighboring structures as being recommended by the
manufacturer [29]. It was shown recently, that compres-
sion and shape of LAA occlusion devices are changing
temporarily within three months after implantation, how-
ever its clinical relevance besides complete LAA closure is
still under debate [30, 31].
Furthermore, accurate differentiation between thrombus
formation and blood stasis within the LAA is challenging
using standard cCTA. An additional delayed cCTA ap-
proximately 70 s after the start of the contrast injection is
recommended [32]. Imaging the patients in prone position
is another theoretical approach in order to minimize the
effects of blood stasis in the LAA. However, data is lacking
about the usefulness of performing cCTA in a prone
position. Dual energy cCTA using calculated iodine maps
has been proposed in order to differentiate accurately
blood stasis from thrombus formation within the LAA of
patients with cardio-embolic stroke [33].
As outlined, post procedural image analysis with cCTA
might bear the potential of a standardized imaging using
defined multi-planar reformations that best display the
complex 3-dimensional shape of the LAA and the device.
In our opinion, cCTA has the main advantage that the im-
ages can be very standardized analyzed and reconstructed
Fig. 7 LOVE - axial (panel a), − sagittal (panel b), and - coronal (panel c) reformations of a 83-year-old female patient who underwent cardiac CTA
9 months after implantation of the ACP® LAA occlusion device. Panels a, b and, c demonstrate no peri-device leak. Panel b shows incomplete lobe
coverage with a small residual LAA lobe. The uncovered LAA lobe is seen between the angle of the sealing part of the ACP device (proximal disk) and
the plane of the LAA ostium (angle in between red lines, marked by white arrow). The contrast filling of the LAA in combination with the clear absence
of a peri-device leak reflects indirectly in-complete endothelialization of the ACP® LAA occlusion device
Fig. 8 LOVE - axial (panel a), − sagittal (panel b), and - coronal (panel c) reformations of a 75-year-old male patient who underwent cardiac CTA
4 months after implantation of a WATCHMAN® LAA occlusion device. Panel a shows a 20° offset of the device around the entry axis to the LAA
(red line in A). The rotation led to an in-complete lobe coverage with a small residual left atrial appendage < 5 mm that is best seen on the LOVE
coronal reformation (arrow in panel c). The residual slight contrast enhancement (* in panels a and b) of the LAA that is approximately 50 %
lower when compared to the contrast enhancement in the left atrium suggests beginning, but still in-complete neo-endothelialization of
the device
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and make quantitative measurements reliable. This is of
particular importance to generate more evidence on rele-
vant clinical questions: (1) What size of a residual LAA is
acceptable with different devices? (2) What size of peri-
device leaks still leads to a complete occlusion over time?
However, the advantages of cCTA for post-implantation
LAA occlusion device evaluation have to outscore the pa-
tients’ individual risk being associated with an additional
radiation dose and additional administration of iodinated
material.
Potential value and limitations of cardiac CTA in the
context of LAA occlusion devices
Cardiac CTA allows the comprehensive non-invasive
visualization of the whole heart including coronary
arteries as well as all important neighboring structures
of the LAA and thus accurate evaluation of post-
implantation evaluation of LAA occlusion devices by the
described LOVE view. The main arguments for the use of
cCTA in this context, besides its non-invasiveness, are
firstly, the whole volume coverage with a high spatial
resolution and secondly, the high reproducibility of the
technique that allows to angulate the isotropic dataset
retrospectively after the procedure in all desired projec-
tions. Thereby generating an investigator’s independency,
cCTA becomes particularly attractive for clinical studies
that require a high standardization of follow-up examina-
tions. Thirdly, image artifacts do not hamper cCTA image
quality because all available LAA occlusion devices do not
lead to metal artifacts such as other metal implants. Based
on our experience, cCTA allows assessing all relevant clin-
ical questions including indirect visualization of LAA oc-
clusion device neo-endothelialization if no peri-device
leak is present. For instance, no contrast enhancement
within the LAA suggests complete neo-endothelialization,
whereas contrast enhancement in the LAA of less than 50
Hounsfield units compared to the enhancement within the
left atrium suggests incomplete neo-endothelialization.
Contrast enhancement within the LAA that is equal to the
left atrium suggests no or very early stages of neo-
endothelialization.
The main concerns with cCTA in the context of LAA
occlusion device evaluation are the additional radiation
dose that is given to the patient. However, with low radi-
ation dose techniques of state-of-the-art CT systems the
radiation dose has been reduced significantly over the
past 5 years [25]. Thus, the risk of ionizing radiation in
this mainly elderly population should be weighted clinic-
ally against potential overseen significant clinical find-
ings potentially being detected by cCTA (such as
thrombus formation or indirect signs of incomplete neo-
endothelialization), whereas their clinical impact still
needs to be proven within prospective clinical studies.
The second relevant concern of cCTA is the need for
iodinated contrast material, which is crucial in patients
with impairment of renal function. Although the amount
of contrast material for the evaluation of LAA occlusion
devices can be reduced to a minimum of 30–40 cc of
contrast in patients with elevated serum creatinine
levels, the indication should be checked strictly in pa-
tients with serum creatinine levels above 1.5 mg/dL.
Additionally, cCTA is more expensive and not as widely
available compared to echocardiography.
Conclusions
This pictorial essay describes a standardized imaging
proposal including examples of (ab)normal findings after
percutaneous implantation of LAA occlusion devices.
Whether the proposed cCTA imaging instructions might
facilitate future clinical follow-up, cost effectiveness and
therapeutic decisions needs to be evaluated further in lar-
ger, prospective and randomized imaging studies evaluat-
ing this specific subset of cardiac patients.
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